Abstract
Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Current Topics in Medicinal Chemistry
Title:Matrix Metallopropteinases in Heart Failure
Volume: 12 Issue: 10
Author(s): Dimitris Tousoulis, Anna-Maria Kampoli, Nikolaos Papageorgiou, Charalambos Antoniades, Gerasimos Siasos, George Latsios, Eleftherios Tsiamis and Christodoulos Stefanadis
Affiliation:
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Abstract: Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Export Options
About this article
Cite this article as:
Tousoulis Dimitris, Kampoli Anna-Maria, Papageorgiou Nikolaos, Antoniades Charalambos, Siasos Gerasimos, Latsios George, Tsiamis Eleftherios and Stefanadis Christodoulos, Matrix Metallopropteinases in Heart Failure, Current Topics in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/1568026611208011181
DOI https://dx.doi.org/10.2174/1568026611208011181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Liver Growth Factor as a Tissue Regenerating Factor in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial
Current Gene Therapy Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Association Between Hypothyroidism and Takotsubo Cardiomyopathy: Analysis of Nationwide Inpatient Sample Database
Reviews on Recent Clinical Trials Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy
Current Cardiology Reviews Beta-Blockers and Cardiovascular Outcomes in Acute Heart Failure with a History of Coronary Artery Disease and an Ejection Fraction ≥ 40%
Current Vascular Pharmacology